GlassScriptPhysician profile
Juan Medaura
NPI 1114217189
$14,216.09
in general payments reported to CMS, 2019-2025
32 companies · $7,197 in 2025
The $7,197 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,838 · 2020: $14.44 · 2021: $76.04 · 2022: $3,449 · 2023: $489 · 2024: $1,153 · 2025: $7,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,290 · Food and Beverage: $3,049 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,290.00 |
| Food and Beverage | $3,048.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $4,962.62 | 2019-2024 | Velphoro |
| Vertex Pharmaceuticals Incorporated | $4,290.00 | 2025 | |
| Recor Medical INC | $1,659.17 | 2025 | Paradise Ultrasound Renal Denervation System |
| Astrazeneca Pharmaceuticals LP | $478.32 | 2023-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $358.61 | 2023-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $316.17 | 2024-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $311.68 | 2020-2025 | Jynarque, Voyxact |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $288.88 | 2022-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $235.09 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.21 | 2023-2025 | Jardiance |
| Amgen INC. | $144.31 | 2023-2025 | Evenity, Prolia, Krystexxa |
| Xeris Pharmaceuticals, INC. | $130.04 | 2024-2025 | Gvoke Hypopen |
| Calliditas Therapeutics US INC. | $130.02 | 2023-2025 | Tarpeyo |
| Akebia Therapeutics INC | $125.82 | 2025 | Vafseo |
| Baxter Healthcare | $99.67 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $85.53 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Nuwellis, INC. | $52.48 | 2021 | |
| Glaxosmithkline, LLC. | $47.95 | 2022-2023 | |
| Esperion Therapeutics, INC. | $41.56 | 2025 | Nexletol |
| Horizon Therapeutics Plc | $30.61 | 2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $27.94 | 2025 | Acthar |
| Ars Pharmaceuticals Operations, INC. | $27.60 | 2025 | Neffy |
| Ardelyx, INC. | $25.07 | 2024 | Ibsrela |
| Exact Sciences Corporation | $21.22 | 2025 | The Cologuard Plus Collection Kit |
| Aurinia Pharma U.S., INC. | $21.08 | 2022 | |
| Embecta Corp. | $20.72 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Kyowa Kirin, INC. | $19.96 | 2023 | Crysvita |
| Rhythm Pharmaceuticals, INC. | $19.50 | 2025 | Imcivree |
| Ascensia Diabetes Care US INC. | $15.86 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $15.72 | 2024 | Baqsimi |
| Mannkind Corporation | $15.44 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.24 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Medaura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.